Photocure granted patent in Europe and Russia for Visonac(TM) in the
treatment of acne
(Thomson Reuters ONE) - Oslo, Norway, November 26, 2009.Both the European Patent Office and the Patent Office in Russia haveissued decisions to grant a patent on Photocure's patent application"PDT Acne". The granted patents will provide protection for the useof the 5-ALA-ester methyl aminolevulinate (MAL- the active ingredientin VisonacTM) and other 5-ALA-esters in the treatment of acne untilNovember 2025."We are very pleased with these decisions giving a strong patentprotection on Photocure's lead dermatology product", says KjetilHestdal, President and CEO of Photocure. "Patent protection of ourproducts is key to succeed in the market".VisonacTM is a photodynamic therapy that combines the VisonacTM creamwith illumination by a red light source to treat acne. Visonac(TM)cream contains MAL. The cream is applied to the acne area to betreated and after a short incubation time, the skin is illuminatedwith red light. The PDT procedure kills bacteria and appears to havea beneficial effect on sebaceous glands and inflammatory cells.About acne:Acne is a common skin condition which affects up to 85% ofadolescents. Each year, US dermatologists register nearly 3 millionvisits concerning acne. Of those who seek medical advice from adermatologist, about 50% have moderate and 20% have severe acne.Current therapies for these patients include oral antibiotics andisotretinoin, both products that may have significant adverseeffects. There is thus a clear medical need for a safe andefficacious topical treatment for acne patients.For further information, contact:President and CEO Kjetil HestdalE-mail: kh(at)photocure.noMobile: +47 913 19 535Office: +47 22 06 22 10CFO Christian FeketeE-mail: cf(at)photocure.noMobile: +47 916 42 938Office: +47 22 06 22 10About Photocure:Photocure is a Norwegian pharmaceutical company listed on the OsloStock Exchange (OSE: PHO). The company develops and sellspharmaceuticals and medical devices for the photodynamic treatmentand diagnosis of cancer and selected dermatology indications.Photocure's commercial activities includes own marketing and sales inselected markets as well as out-licensing to leading pharmaceuticalcompanies on a regional or global basis prior to phase III.Photocure has one proprietary pharmaceutical product on the market:Hexvix®, for the diagnosis of bladder cancer. Hexvix is approved inEU and under priority review by FDA in the US. In addition, thecompany has developed a proprietary light source, which is used incombination with the Visonac(TM) cream. Through worldwide studies,Photocure is continuously testing its products for new indications,and the aim is to develop a pipeline of follow-on products based onthe Photocure Technology(TM) platform.Photocure® and Hexvix® are registered trademarks of Photocure ASA.For more information about Photocure, visit our website atwww.photocure.com.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 26.11.2009 - 16:15 Uhr
Sprache: Deutsch
News-ID 8899
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 192 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Photocure granted patent in Europe and Russia for Visonac(TM) in the
treatment of acne"
steht unter der journalistisch-redaktionellen Verantwortung von
Photocure ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
